PHARMACY

NACDS names Giancamilli to head board of directors

BY Alaric DeArment

NEW YORK The National Association of Chain Drug Stores’ new chairman of the board has officially started work.

Andrew Giancamilli, chief executive officer of Katz Group North America and Snyder’s Drug Stores began his tenure Thursday, succeeding Warren Bryant. Giancamilli will continue as chairman of the board until April 2010. 

A pharmacist by training, Giancamilli began his career at Perry Drug Stores in 1975, becoming president and chief executive officer in 1993 and taking executive positions at Kmart between 1995 and 2001. He worked at Canadian Tire from 2001 until 2003, when he joined Katz Group. Katz Group is one of the largest integrated retail pharmacy networks in North America and includes Snyder’s Drug Stores in the Midwest and the Rexall chain in Canada. 

“I’m very proud to serve NACDS and the industry in this critical role and look forward to working with the board on progressive initiatives,” Giancamilli said in a statement. “Promoting and advocating on the value of pharmacy to primary care and prevention is essential to not only improving the overall health of patients but also in moving the industry forward.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Fougera endows NACDS scholarship fund

BY Jim Frederick

NEW YORK With a major endowment from Fougera, the National Association of Chain Drug Stores Foundation last night inaugurated the Edmond Fougera Scholarship Fund at the 10th Annual NACDS Foundation Dinner.

To establish the fund, Fougera president and chief executive officer Paul McGarty presented a $160,000 contribution to Foundation chairman Steven Anderson. The money, a major addition to the NACDS Foundation Student Scholarship Program, will generate scholarships to be awarded each year to exceptional pharmacy students who have demonstrated strong leadership and a commitment to community pharmacy.

To establish the fund, Fougera president and chief executive officer Paul McGarty presented a $160,000 contribution to Foundation chairman Steven Anderson. The money, a major addition to the NACDS Foundation Student Scholarship Program, will generate scholarships to be awarded each year to exceptional pharmacy students who have demonstrated strong leadership and a commitment to community pharmacy.

“Advancing community pharmacy by supporting the next generation of professionals is an honorable mission, and one that Fougera is proud to be a part of,” McGarty said during the presentation.

“Pharmacy students will play a critical role in the future of healthcare delivery for patients,” said Anderson. “We are pleased to partner with Fougera in establishing the Edmond Fougera Scholarship Fund and help students meet their potential and continue to advance the profession of pharmacy.”

The company was founded by French immigrant Edmond Fougera in 1849 when he opened a retail pharmacy in Brooklyn, New York, and is a supplier of topical dermatologic applications.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Study: Generics just as good as branded heart disease drugs

BY Alaric DeArment

NEW YORK Generic drugs for treating heart disease work as well as branded drugs, according to a new study.

The study, published Wednesday in the Journal of the American Medical Association, was based on 47 studies of nine drugs published in journals such as Medline and International Pharmaceutical Abstracts between January 1984 and August 2008. The researchers, from Harvard Medical School, found no difference in how well patients did when given branded drugs or generic equivalents for cholesterol, hypertension or prevention of heart attacks.

Generic drugs can cost between 30 and 80 percent less than branded drugs. The Food and Drug Administration received authority to approve generic drugs in 1984, with the passage of the Hatch-Waxman Act, though it does not have a way to approve drugs that mimic the effects of biotech medications.

“Today’s article in the respected medical journal JAMA confirms that generic medicines are as safe and effective as their brand-name counterparts,” Generic Pharmaceutical Association president and chief executive Kathleen Jaeger said in a statement Wednesday. “This scientific review is the latest in a growing number of authoritative statements from the FDA and others proving that it is safe to substitute an FDA-approved generic medicine for a brand-name product.”

This year, Jaeger said, legislatures in 33 state have introduced “carve-out” bills designed to place limits on when generic drugs may be used.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?